NCT Number: NCT04471974
Phase: Phase 2
Trial Summary: This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other pla – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Rahul Aggarwal
Acronym:
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives